查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球他汀类药物市场 - 全球产业分析、规模、份额、成长、趋势、预测 (2031) - 按药物类别、按疗法、按最终用户、按地区
市场调查报告书
商品编码
1410564

全球他汀类药物市场 - 全球产业分析、规模、份额、成长、趋势、预测 (2031) - 按药物类别、按疗法、按最终用户、按地区

Statins Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)
出版日期: | 出版商: Fairfield Market Research | 英文 250 Pages | 商品交期: 2-5个工作天内

价格
简介目录

全球他汀类药物市场规模处于稳定成长轨道，预计2024年将达154亿美元，2031年将达210亿美元。

全球对他汀类药物的需求受到全球高胆固醇和肥胖症盛行率日益增加的显着影响。生活方式的改变和久坐的生活方式会导致高胆固醇水平，这使得他汀类药物成为胆固醇管理的重要解决方案。

他汀类药物在对抗高胆固醇水平方面发挥着重要作用，而仅靠改变生活方式很难控制高胆固醇水平。此外，意识措施和先进的医疗设施也促进了他汀类药物需求的成长。

此外，包含他汀类药物与依折麦布等其他降胆固醇药物的联合疗法的采用预计将进一步推动全球市场。他汀类药物和依折麦布的联合治疗有望实现接近正常的血脂水平并降低心血管疾病的风险。

儘管他汀类药物市场有望成长，但挑战仍然存在，主要与高製造成本和製造过程的复杂性有关。此外，透过严格的分析表征和监管审批程序建立生物相似性仍然是一个耗时且昂贵的过程。

然而，研发投资的增加、对改善医疗设施的强烈兴趣以及公共和私营部门之间的战略伙伴关係预计将为他汀类药物製造商提供成长机会。

本报告检视了全球他汀类药物市场，并提供了市场概况，包括按药物类别、疗法、最终用户、地区划分的趋势以及进入市场的公司的竞争趋势。

目录

第一章执行摘要

第二章市场概况

  • 市场定义与细分
  • 市场动态
  • 价值链分析
  • 波特五力分析
  • COVID-19 影响分析
  • 乌克兰与俄罗斯衝突的影响
  • 经济概况
  • PESTLE分析

第三章 2018-2023年生产与贸易统计

第四章 2018-2023年价格分析

第五章 2018-2031 年全球他汀类药物市场展望

  • 全球他汀类药物市场展望，依药物类别、价值（十亿美元）、销量，2018-2031 年
  • 全球他汀类药物市场展望，依治疗方法、价值（十亿美元）、数量，2018-2031 年
  • 全球他汀类药物市场展望（按最终用户）、价值（十亿美元）、销量，2018-2031 年
  • 全球他汀类药物市场展望，按地区、价值（十亿美元）、销量，2018-2031 年

第六章 2018-2031 年北美他汀类药物市场展望

第七章 2018-2031 年欧洲他汀类药物市场展望

第八章 2018-2031 年亚太地区他汀类药物市场展望

第 9 章 2018-2031 年拉丁美洲他汀类药物市场展望

第十章 2018-2031 年中东及非洲他汀类药物市场展望

第十一章竞争格局

  • 按最终用户和处理划分的热图
  • 2023 年公司市场份额分析
  • 竞争力仪表板
  • 公司简介
    • Pfizer Inc.
    • AstraZeneca plc
    • Novartis International AG
    • GlaxoSmithKline plc
    • Merck & Co., Inc.
    • Biocon
    • Aurobindo Pharma Ltd
    • Concord Biotech

第十二章附录

简介目录

North America Dominates the Market, with the United States Leading in Statin Usage

Rising Obesity and Cardiovascular Disease Cases Boost Demand for Statins Worldwide

The global statins market is on a steady growth trajectory and is expected to reach a valuation of US$ 21 billion by 2031. In 2024, the market was valued at US$ 15.4 billion.

Market Dynamics

The global demand for statins is being significantly influenced by the increasing incidence of high cholesterol and obesity cases worldwide. Lifestyle changes and sedentary habits have led to a rise in high cholesterol levels, making statins an essential solution for cholesterol management.

Statins play a crucial role in addressing high cholesterol levels that are difficult to control solely through lifestyle modifications. Additionally, awareness initiatives and advanced healthcare facilities are contributing to the growing demand for statins.

Moreover, the adoption of combination therapies that include statins alongside other cholesterol-lowering medications, such as ezetimibe, is expected to further drive the global market. Statin-ezetimibe combination therapy has shown promise in achieving near-normal lipid profiles, reducing the risk of cardiovascular diseases.

Challenges and Opportunities

While the statins market is poised for growth, challenges persist, primarily related to high manufacturing costs and the complexity of the production process. Additionally, establishing biosimilarity through rigorous analytical characterization and regulatory approval procedures remains a time-consuming and costly process.

However, increasing investments in research and development, a strong focus on improving healthcare facilities, and strategic collaborations between public and private entities are expected to provide growth opportunities for statin manufacturers.

Regional Analysis

North America is at the forefront of the global statins market and is poised to maintain its dominance throughout the forecast period. The region has a significant population suffering from cardiovascular diseases, diabetes, and obesity, driving the demand for effective cholesterol management solutions.

The United States is expected to lead the statins market in North America, with organizations like the American Heart Association and the American College of Cardiology issuing guidelines that recommend statin usage for individuals at risk of heart attacks.

Product Analysis

Statins are a class of drugs used to lower blood cholesterol levels, particularly low-density lipoprotein (LDL) cholesterol. The market for statins has witnessed steady growth, driven by increased healthcare awareness and the rising prevalence of cholesterol-related conditions.

While maintaining a healthy lifestyle can help manage cholesterol, sedentary habits have contributed to a growing need for statin therapy, particularly among the elderly population.

Key Players

Prominent players in the global statins market include: Pfizer Inc., AstraZeneca plc, Novartis International AG, GlaxoSmithKline plc, Merck & Co., Inc., Biocon, Aurobindo Pharma Ltd, and Concord Biotech.

Statins Industry Research Segmentation

By Drug Class:

  • Astrovastatins
  • Fluvastatins
  • Lovastatins
  • Pravastatins
  • Simvastatins
  • Others

By Therapeutic Treatment:

  • Cardiovascular Disorders
  • Obesity
  • Inflammatory Disorders
  • Others

By End User:

  • Hospitals
  • Clinics

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Statins Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value and Volume, 2023
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Production Output and Trade Statistics, 2018 - 2023

  • 3.1. Global Statins Production Output, by Region, Value (US$ Bn) and Volume, 2018 - 2023
    • 3.1.1. North America
    • 3.1.2. Europe
    • 3.1.3. Asia Pacific
    • 3.1.4. Latin America
    • 3.1.5. Middle East and Africa

4. Price Analysis, 2018 - 2023

  • 4.1. Global Average Price Analysis by Drug Class, 2018 - 2023
  • 4.2. Prominent Factor Affecting Statins Prices
  • 4.3. Global Average Price Analysis by Region

5. Global Statins Market Outlook, 2018 - 2031

  • 5.1. Global Statins Market Outlook, by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
    • 5.1.1. Key Highlights
      • 5.1.1.1. Astrovastatins
      • 5.1.1.2. Fluvastatins
      • 5.1.1.3. Lovastatins
      • 5.1.1.4. Pravastatins
      • 5.1.1.5. Simvastatins
      • 5.1.1.6. Others
  • 5.2. Global Statins Market Outlook, by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. Cardiovascular Disorders
      • 5.2.1.2. Obesity
      • 5.2.1.3. Inflammatory Disorders
      • 5.2.1.4. Others
  • 5.3. Global Statins Market Outlook, by End User, Value (US$ Bn) and Volume, 2018 - 2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Hospitals
      • 5.3.1.2. Clinics
  • 5.4. Global Statins Market Outlook, by Region, Value (US$ Bn) and Volume, 2018 - 2031
    • 5.4.1. Key Highlights
      • 5.4.1.1. North America
      • 5.4.1.2. Europe
      • 5.4.1.3. Asia Pacific
      • 5.4.1.4. Latin America
      • 5.4.1.5. Middle East & Africa

6. North America Statins Market Outlook, 2018 - 2031

  • 6.1. North America Statins Market Outlook, by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
    • 6.1.1. Key Highlights
      • 6.1.1.1. Astrovastatins
      • 6.1.1.2. Fluvastatins
      • 6.1.1.3. Lovastatins
      • 6.1.1.4. Pravastatins
      • 6.1.1.5. Simvastatins
      • 6.1.1.6. Others
  • 6.2. North America Statins Market Outlook, by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. Cardiovascular Disorders
      • 6.2.1.2. Obesity
      • 6.2.1.3. Inflammatory Disorders
      • 6.2.1.4. Others
  • 6.3. North America Statins Market Outlook, by End User, Value (US$ Bn) and Volume, 2018 - 2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. Hospitals
      • 6.3.1.2. Clinics
    • 6.3.2. BPS Analysis/Market Attractiveness Analysis
  • 6.4. North America Statins Market Outlook, by Country, Value (US$ Bn) and Volume, 2018 - 2031
    • 6.4.1. Key Highlights
      • 6.4.1.1. U.S. Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
      • 6.4.1.2. U.S. Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
      • 6.4.1.3. U.S. Statins Market by End User, Value (US$ Bn) and Volume, 2018 - 2031
      • 6.4.1.4. Canada Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
      • 6.4.1.5. Canada Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
      • 6.4.1.6. Canada Statins Market by End User, Value (US$ Bn) and Volume, 2018 - 2031
    • 6.4.2. BPS Analysis/Market Attractiveness Analysis

7. Europe Statins Market Outlook, 2018 - 2031

  • 7.1. Europe Statins Market Outlook, by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
    • 7.1.1. Key Highlights
      • 7.1.1.1. Astrovastatins
      • 7.1.1.2. Fluvastatins
      • 7.1.1.3. Lovastatins
      • 7.1.1.4. Pravastatins
      • 7.1.1.5. Simvastatins
      • 7.1.1.6. Others
  • 7.2. Europe Statins Market Outlook, by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
    • 7.2.1. Key Highlights
      • 7.2.1.1. Cardiovascular Disorders
      • 7.2.1.2. Obesity
      • 7.2.1.3. Inflammatory Disorders
      • 7.2.1.4. Others
  • 7.3. Europe Statins Market Outlook, by End User, Value (US$ Bn) and Volume, 2018 - 2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Hospitals
      • 7.3.1.2. Clinics
    • 7.3.2. Attractiveness Analysis
  • 7.4. Europe Statins Market Outlook, by Country, Value (US$ Bn) and Volume, 2018 - 2031
    • 7.4.1. Key Highlights
      • 7.4.1.1. Germany Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
      • 7.4.1.2. Germany Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
      • 7.4.1.3. Germany Statins Market by End User, Value (US$ Bn) and Volume, 2018 - 2031
      • 7.4.1.4. U.K. Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
      • 7.4.1.5. U.K. Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
      • 7.4.1.6. U.K. Statins Market by End User, Value (US$ Bn) and Volume, 2018 - 2031
      • 7.4.1.7. France Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
      • 7.4.1.8. France Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
      • 7.4.1.9. France Statins Market by End User, Value (US$ Bn) and Volume, 2018 - 2031
      • 7.4.1.10. Italy Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
      • 7.4.1.11. Italy Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
      • 7.4.1.12. Italy Statins Market by End User, Value (US$ Bn) and Volume, 2018 - 2031
      • 7.4.1.13. Turkey Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
      • 7.4.1.14. Turkey Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
      • 7.4.1.15. Turkey Statins Market by End User, Value (US$ Bn) and Volume, 2018 - 2031
      • 7.4.1.16. Russia Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
      • 7.4.1.17. Russia Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
      • 7.4.1.18. Russia Statins Market by End User, Value (US$ Bn) and Volume, 2018 - 2031
      • 7.4.1.19. Rest of Europe Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
      • 7.4.1.20. Rest of Europe Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
      • 7.4.1.21. Rest of Europe Statins Market by End User, Value (US$ Bn) and Volume, 2018 - 2031
    • 7.4.2. BPS Analysis/Market Attractiveness Analysis

8. Asia Pacific Statins Market Outlook, 2018 - 2031

  • 8.1. Asia Pacific Statins Market Outlook, by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
    • 8.1.1. Key Highlights
      • 8.1.1.1. Astrovastatins
      • 8.1.1.2. Fluvastatins
      • 8.1.1.3. Lovastatins
      • 8.1.1.4. Pravastatins
      • 8.1.1.5. Simvastatins
      • 8.1.1.6. Others
  • 8.2. Asia Pacific Statins Market Outlook, by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. Cardiovascular Disorders
      • 8.2.1.2. Obesity
      • 8.2.1.3. Inflammatory Disorders
      • 8.2.1.4. Others
  • 8.3. Asia Pacific Statins Market Outlook, by End User, Value (US$ Bn) and Volume, 2018 - 2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. Hospitals
      • 8.3.1.2. Clinics
    • 8.3.2. BPS Analysis/Market Attractiveness Analysis
  • 8.4. Asia Pacific Statins Market Outlook, by Country, Value (US$ Bn) and Volume, 2018 - 2031
    • 8.4.1. Key Highlights
      • 8.4.1.1. China Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
      • 8.4.1.2. China Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
      • 8.4.1.3. China Statins Market by End User, Value (US$ Bn) and Volume, 2018 - 2031
      • 8.4.1.4. Japan Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
      • 8.4.1.5. Japan Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
      • 8.4.1.6. Japan Statins Market by End User, Value (US$ Bn) and Volume, 2018 - 2031
      • 8.4.1.7. South Korea Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
      • 8.4.1.8. South Korea Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
      • 8.4.1.9. South Korea Statins Market by End User, Value (US$ Bn) and Volume, 2018 - 2031
      • 8.4.1.10. India Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
      • 8.4.1.11. India Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
      • 8.4.1.12. India Statins Market by End User, Value (US$ Bn) and Volume, 2018 - 2031
      • 8.4.1.13. Southeast Asia Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
      • 8.4.1.14. Southeast Asia Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
      • 8.4.1.15. Southeast Asia Statins Market by End User, Value (US$ Bn) and Volume, 2018 - 2031
      • 8.4.1.16. Rest of Asia Pacific Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
      • 8.4.1.17. Rest of Asia Pacific Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
      • 8.4.1.18. Rest of Asia Pacific Statins Market by End User, Value (US$ Bn) and Volume, 2018 - 2031
    • 8.4.2. BPS Analysis/Market Attractiveness Analysis

9. Latin America Statins Market Outlook, 2018 - 2031

  • 9.1. Latin America Statins Market Outlook, by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
    • 9.1.1. Key Highlights
      • 9.1.1.1. Astrovastatins
      • 9.1.1.2. Fluvastatins
      • 9.1.1.3. Lovastatins
      • 9.1.1.4. Pravastatins
      • 9.1.1.5. Simvastatins
      • 9.1.1.6. Others
  • 9.2. Latin America Statins Market Outlook, by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
    • 9.2.1. Key Highlights
      • 9.2.1.1. Cardiovascular Disorders
      • 9.2.1.2. Obesity
      • 9.2.1.3. Inflammatory Disorders
      • 9.2.1.4. Others
  • 9.3. Latin America Statins Market Outlook, by End User, Value (US$ Bn) and Volume, 2018 - 2031
    • 9.3.1. Key Highlights
      • 9.3.1.1. Hospitals
      • 9.3.1.2. Clinics
    • 9.3.2. BPS Analysis/Market Attractiveness Analysis
  • 9.4. Latin America Statins Market Outlook, by Country, Value (US$ Bn) and Volume, 2018 - 2031
    • 9.4.1. Key Highlights
      • 9.4.1.1. Brazil Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
      • 9.4.1.2. Brazil Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
      • 9.4.1.3. Brazil Statins Market by End User, Value (US$ Bn) and Volume, 2018 - 2031
      • 9.4.1.4. Mexico Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
      • 9.4.1.5. Mexico Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
      • 9.4.1.6. Mexico Statins Market by End User, Value (US$ Bn) and Volume, 2018 - 2031
      • 9.4.1.7. Argentina Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
      • 9.4.1.8. Argentina Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
      • 9.4.1.9. Argentina Statins Market by End User, Value (US$ Bn) and Volume, 2018 - 2031
      • 9.4.1.10. Rest of Latin America Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
      • 9.4.1.11. Rest of Latin America Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
      • 9.4.1.12. Rest of Latin America Statins Market by End User, Value (US$ Bn) and Volume, 2018 - 2031
    • 9.4.2. BPS Analysis/Market Attractiveness Analysis

10. Middle East & Africa Statins Market Outlook, 2018 - 2031

  • 10.1. Middle East & Africa Statins Market Outlook, by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
    • 10.1.1. Key Highlights
      • 10.1.1.1. Astrovastatins
      • 10.1.1.2. Fluvastatins
      • 10.1.1.3. Lovastatins
      • 10.1.1.4. Pravastatins
      • 10.1.1.5. Simvastatins
      • 10.1.1.6. Others
  • 10.2. Middle East & Africa Statins Market Outlook, by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
    • 10.2.1. Key Highlights
      • 10.2.1.1. Cardiovascular Disorders
      • 10.2.1.2. Obesity
      • 10.2.1.3. Inflammatory Disorders
      • 10.2.1.4. Others
  • 10.3. Middle East & Africa Statins Market Outlook, by End User, Value (US$ Bn) and Volume, 2018 - 2031
    • 10.3.1. Key Highlights
      • 10.3.1.1. Hospitals
      • 10.3.1.2. Clinics
    • 10.3.2. BPS Analysis/Market Attractiveness Analysis
  • 10.4. Middle East & Africa Statins Market Outlook, by Country, Value (US$ Bn) and Volume, 2018 - 2031
    • 10.4.1. Key Highlights
      • 10.4.1.1. GCC Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
      • 10.4.1.2. GCC Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
      • 10.4.1.3. GCC Statins Market by End User, Value (US$ Bn) and Volume, 2018 - 2031
      • 10.4.1.4. South Africa Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
      • 10.4.1.5. South Africa Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
      • 10.4.1.6. South Africa Statins Market by End User, Value (US$ Bn) and Volume, 2018 - 2031
      • 10.4.1.7. Egypt Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
      • 10.4.1.8. Egypt Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
      • 10.4.1.9. Egypt Statins Market by End User, Value (US$ Bn) and Volume, 2018 - 2031
      • 10.4.1.10. Nigeria Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
      • 10.4.1.11. Nigeria Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
      • 10.4.1.12. Nigeria Statins Market by End User, Value (US$ Bn) and Volume, 2018 - 2031
      • 10.4.1.13. Rest of Middle East & Africa Statins Market by Drug Class, Value (US$ Bn) and Volume, 2018 - 2031
      • 10.4.1.14. Rest of Middle East & Africa Statins Market by Therapeutic Treatment, Value (US$ Bn) and Volume, 2018 - 2031
      • 10.4.1.15. Rest of Middle East & Africa Statins Market by End User, Value (US$ Bn) and Volume, 2018 - 2031
    • 10.4.2. BPS Analysis/Market Attractiveness Analysis

11. Competitive Landscape

  • 11.1. By End User vs by Therapeutic Treatment Heatmap
  • 11.2. Company Market Share Analysis, 2023
  • 11.3. Competitive Dashboard
  • 11.4. Company Profiles
    • 11.4.1. Pfizer Inc.
      • 11.4.1.1. Company Overview
      • 11.4.1.2. Product Portfolio
      • 11.4.1.3. Financial Overview
      • 11.4.1.4. Business Strategies and Development
    • 11.4.2. AstraZeneca plc
      • 11.4.2.1. Company Overview
      • 11.4.2.2. Product Portfolio
      • 11.4.2.3. Financial Overview
      • 11.4.2.4. Business Strategies and Development
    • 11.4.3. Novartis International AG
      • 11.4.3.1. Company Overview
      • 11.4.3.2. Product Portfolio
      • 11.4.3.3. Financial Overview
      • 11.4.3.4. Business Strategies and Development
    • 11.4.4. GlaxoSmithKline plc
      • 11.4.4.1. Company Overview
      • 11.4.4.2. Product Portfolio
      • 11.4.4.3. Financial Overview
      • 11.4.4.4. Business Strategies and Development
    • 11.4.5. Merck & Co., Inc.
      • 11.4.5.1. Company Overview
      • 11.4.5.2. Product Portfolio
      • 11.4.5.3. Financial Overview
      • 11.4.5.4. Business Strategies and Development
    • 11.4.6. Biocon
      • 11.4.6.1. Company Overview
      • 11.4.6.2. Product Portfolio
      • 11.4.6.3. Financial Overview
      • 11.4.6.4. Business Strategies and Development
    • 11.4.7. Aurobindo Pharma Ltd
      • 11.4.7.1. Company Overview
      • 11.4.7.2. Product Portfolio
      • 11.4.7.3. Financial Overview
      • 11.4.7.4. Business Strategies and Development
    • 11.4.8. Concord Biotech
      • 11.4.8.1. Company Overview
      • 11.4.8.2. Product Portfolio
      • 11.4.8.3. Financial Overview
      • 11.4.8.4. Business Strategies and Development

12. Appendix

  • 12.1. Research Methodology
  • 12.2. Report Assumptions
  • 12.3. Acronyms and Abbreviations